News

Biomednewsbreaks - Nanoviricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success In Humanized Animal Study
NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage developer of broad-spectrum antivirals using host-mimetic nanomedicine, announced promis ...
Measles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...
Pharmabiz4d
NanoViricides designs trial protocol for phase II MPox Clade Ia with a novel drug NV-387 for treating MPox disease
Shelton, Connecticut Thursday, July 17, 2025, 18:00 Hrs [IST] ...
Biomednewsbreaks - Nanoviricides, Inc. (NYSE American: NNVC) Highlights Mpox Drug Progress As WHO Extends Global Health Emergency
NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage pioneer in host-mimetic nanomedicine, affirmed its preparedness to address the continued ...
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...
NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox
NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...
NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case
NanoViricides highlighted several key reasons for prioritizing MPox as the first indication for NV-387's Phase II development, even with strong efficacy data in animal studies for other major viral ...
AZ Central1mon
NanoViricides Measles Drug Development Animal Study is Imminent
NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral ...
The Indianapolis Star1mon
NanoViricides to Present at the BIO International Convention ... - IndyStar
NanoViricides is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation of its Lead Drug candidate, NV-387, for the Treatment of MPOX disease, in response to the continuing ...
Des Moines Register1mon
NanoViricides to Present at the BIO International Convention in Boston ...
NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral ...